Prognostic factors in lung cancer with brain metastasis
Background and purpose: Metastasis to the brain develops in 25% of all patients with lung cancer. Although the outcome is usually poor, there seems to be a subset of patients with favorable prognostic factors who may live longer. Prognostic factors were analyzed retrospectively in 103 patients with...
Gespeichert in:
| Veröffentlicht in: | Radiotherapy and oncology 1998, Vol.46 (1), p.33-38 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Radiotherapy and oncology |
| container_volume | 46 |
| creator | Şen, Mehmet Demiral, Ayşe S Çetingöz, Riza Alanyali, Hilmi Akman, Fadime Şentürk, Dilek Kinay, Münir |
| description | Background and purpose: Metastasis to the brain develops in 25% of all patients with lung cancer. Although the outcome is usually poor, there seems to be a subset of patients with favorable prognostic factors who may live longer. Prognostic factors were analyzed retrospectively in 103 patients with brain metastases from lung carcinoma to identify patients who would benefit from more intensive treatment strategies.
Materials and methods: Between October 1991 and December 1994, 103 patients with brain metastasis from lung cancer were irradiated with palliative intent. Palliation was defined as 50% or more regression of neurological signs and symptoms 2 weeks after the completion of cranial radiotherapy. Local (related to the lung tumor) symptom status at the time of brain metastasis, the presence of metastases other than brain, multiplicity of brain metastases on CT scan and time of occurrence of brain metastasis were the factors which were evaluated with multivariate analysis.
Results: Palliation was accomplished in 85% of cases. Palliation duration ranged from 0.5 to 54 months (median 3 months). The overall median survival was 5 months. Only one patient is under follow-up without any symptoms related to the brain metastasis. According to the multivariate analysis survival was significantly decreased in the presence of symptoms related to the primary tumor (
P=0.001).
Conclusion: The presence of symptoms related to the primary tumor at the time of brain metastasis is one of the factors that can be used to distinguish patients with a favorable outcome. In patients with favorable prognostic factors and thus longer survival probability, the role of boost dose after whole brain radiotherapy or surgical resection in suitable cases needs to be investigated. |
| doi_str_mv | 10.1016/S0167-8140(97)00124-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79707029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814097001242</els_id><sourcerecordid>79707029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-9518a87ec9b29b428db2eb7b7ee3a88de311e2324c710762eb32b10ed64f75763</originalsourceid><addsrcrecordid>eNqFkNtKAzEQhoMotVYfobBXoherSfYwyZVI8QQFBfU6JNnZGtnu1mRX8e1ND_RWGGZg_n9mmI-QKaNXjLLy-jUmSAXL6YWES0oZz1N-QMZMgEypEHBIxnvLMTkJ4ZNSymkGIzKSuRCMF2MCL75btF3onU1qbfvOh8S1STO0i8Tq1qJPflz_kRivY3uJvQ4xXDglR7VuAp7t6oS839-9zR7T-fPD0-x2ntqspH0qCya0ALTScGlyLirD0YABxEwLUWHGGPKM5xYYhTJqGTeMYlXmNRRQZhNyvt278t3XgKFXSxcsNo1usRuCAgkUKJfRWGyN1ncheKzVyrul9r-KUbUGpjbA1JqGkqA2wBSPc9PdgcEssdpP7QhF_WarY_zy26FXwTqMYCrn0faq6tw_F_4AKYZ5tw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79707029</pqid></control><display><type>article</type><title>Prognostic factors in lung cancer with brain metastasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Şen, Mehmet ; Demiral, Ayşe S ; Çetingöz, Riza ; Alanyali, Hilmi ; Akman, Fadime ; Şentürk, Dilek ; Kinay, Münir</creator><creatorcontrib>Şen, Mehmet ; Demiral, Ayşe S ; Çetingöz, Riza ; Alanyali, Hilmi ; Akman, Fadime ; Şentürk, Dilek ; Kinay, Münir</creatorcontrib><description>Background and purpose: Metastasis to the brain develops in 25% of all patients with lung cancer. Although the outcome is usually poor, there seems to be a subset of patients with favorable prognostic factors who may live longer. Prognostic factors were analyzed retrospectively in 103 patients with brain metastases from lung carcinoma to identify patients who would benefit from more intensive treatment strategies.
Materials and methods: Between October 1991 and December 1994, 103 patients with brain metastasis from lung cancer were irradiated with palliative intent. Palliation was defined as 50% or more regression of neurological signs and symptoms 2 weeks after the completion of cranial radiotherapy. Local (related to the lung tumor) symptom status at the time of brain metastasis, the presence of metastases other than brain, multiplicity of brain metastases on CT scan and time of occurrence of brain metastasis were the factors which were evaluated with multivariate analysis.
Results: Palliation was accomplished in 85% of cases. Palliation duration ranged from 0.5 to 54 months (median 3 months). The overall median survival was 5 months. Only one patient is under follow-up without any symptoms related to the brain metastasis. According to the multivariate analysis survival was significantly decreased in the presence of symptoms related to the primary tumor (
P=0.001).
Conclusion: The presence of symptoms related to the primary tumor at the time of brain metastasis is one of the factors that can be used to distinguish patients with a favorable outcome. In patients with favorable prognostic factors and thus longer survival probability, the role of boost dose after whole brain radiotherapy or surgical resection in suitable cases needs to be investigated.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/S0167-8140(97)00124-2</identifier><identifier>PMID: 9488125</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Brain metastases ; Brain Neoplasms - mortality ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - secondary ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Small Cell - mortality ; Carcinoma, Small Cell - radiotherapy ; Carcinoma, Small Cell - secondary ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - secondary ; Female ; Follow-Up Studies ; Humans ; Lung cancer ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Multivariate Analysis ; Palliative Care ; Prognosis ; Prognostic factors ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate ; Tomography, X-Ray Computed</subject><ispartof>Radiotherapy and oncology, 1998, Vol.46 (1), p.33-38</ispartof><rights>1998 Elsevier Science Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-9518a87ec9b29b428db2eb7b7ee3a88de311e2324c710762eb32b10ed64f75763</citedby><cites>FETCH-LOGICAL-c360t-9518a87ec9b29b428db2eb7b7ee3a88de311e2324c710762eb32b10ed64f75763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167814097001242$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9488125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Şen, Mehmet</creatorcontrib><creatorcontrib>Demiral, Ayşe S</creatorcontrib><creatorcontrib>Çetingöz, Riza</creatorcontrib><creatorcontrib>Alanyali, Hilmi</creatorcontrib><creatorcontrib>Akman, Fadime</creatorcontrib><creatorcontrib>Şentürk, Dilek</creatorcontrib><creatorcontrib>Kinay, Münir</creatorcontrib><title>Prognostic factors in lung cancer with brain metastasis</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Background and purpose: Metastasis to the brain develops in 25% of all patients with lung cancer. Although the outcome is usually poor, there seems to be a subset of patients with favorable prognostic factors who may live longer. Prognostic factors were analyzed retrospectively in 103 patients with brain metastases from lung carcinoma to identify patients who would benefit from more intensive treatment strategies.
Materials and methods: Between October 1991 and December 1994, 103 patients with brain metastasis from lung cancer were irradiated with palliative intent. Palliation was defined as 50% or more regression of neurological signs and symptoms 2 weeks after the completion of cranial radiotherapy. Local (related to the lung tumor) symptom status at the time of brain metastasis, the presence of metastases other than brain, multiplicity of brain metastases on CT scan and time of occurrence of brain metastasis were the factors which were evaluated with multivariate analysis.
Results: Palliation was accomplished in 85% of cases. Palliation duration ranged from 0.5 to 54 months (median 3 months). The overall median survival was 5 months. Only one patient is under follow-up without any symptoms related to the brain metastasis. According to the multivariate analysis survival was significantly decreased in the presence of symptoms related to the primary tumor (
P=0.001).
Conclusion: The presence of symptoms related to the primary tumor at the time of brain metastasis is one of the factors that can be used to distinguish patients with a favorable outcome. In patients with favorable prognostic factors and thus longer survival probability, the role of boost dose after whole brain radiotherapy or surgical resection in suitable cases needs to be investigated.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain metastases</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Small Cell - mortality</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Carcinoma, Small Cell - secondary</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Palliative Care</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkNtKAzEQhoMotVYfobBXoherSfYwyZVI8QQFBfU6JNnZGtnu1mRX8e1ND_RWGGZg_n9mmI-QKaNXjLLy-jUmSAXL6YWES0oZz1N-QMZMgEypEHBIxnvLMTkJ4ZNSymkGIzKSuRCMF2MCL75btF3onU1qbfvOh8S1STO0i8Tq1qJPflz_kRivY3uJvQ4xXDglR7VuAp7t6oS839-9zR7T-fPD0-x2ntqspH0qCya0ALTScGlyLirD0YABxEwLUWHGGPKM5xYYhTJqGTeMYlXmNRRQZhNyvt278t3XgKFXSxcsNo1usRuCAgkUKJfRWGyN1ncheKzVyrul9r-KUbUGpjbA1JqGkqA2wBSPc9PdgcEssdpP7QhF_WarY_zy26FXwTqMYCrn0faq6tw_F_4AKYZ5tw</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Şen, Mehmet</creator><creator>Demiral, Ayşe S</creator><creator>Çetingöz, Riza</creator><creator>Alanyali, Hilmi</creator><creator>Akman, Fadime</creator><creator>Şentürk, Dilek</creator><creator>Kinay, Münir</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Prognostic factors in lung cancer with brain metastasis</title><author>Şen, Mehmet ; Demiral, Ayşe S ; Çetingöz, Riza ; Alanyali, Hilmi ; Akman, Fadime ; Şentürk, Dilek ; Kinay, Münir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-9518a87ec9b29b428db2eb7b7ee3a88de311e2324c710762eb32b10ed64f75763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain metastases</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Small Cell - mortality</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Carcinoma, Small Cell - secondary</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Palliative Care</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Şen, Mehmet</creatorcontrib><creatorcontrib>Demiral, Ayşe S</creatorcontrib><creatorcontrib>Çetingöz, Riza</creatorcontrib><creatorcontrib>Alanyali, Hilmi</creatorcontrib><creatorcontrib>Akman, Fadime</creatorcontrib><creatorcontrib>Şentürk, Dilek</creatorcontrib><creatorcontrib>Kinay, Münir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Şen, Mehmet</au><au>Demiral, Ayşe S</au><au>Çetingöz, Riza</au><au>Alanyali, Hilmi</au><au>Akman, Fadime</au><au>Şentürk, Dilek</au><au>Kinay, Münir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors in lung cancer with brain metastasis</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>1998</date><risdate>1998</risdate><volume>46</volume><issue>1</issue><spage>33</spage><epage>38</epage><pages>33-38</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Background and purpose: Metastasis to the brain develops in 25% of all patients with lung cancer. Although the outcome is usually poor, there seems to be a subset of patients with favorable prognostic factors who may live longer. Prognostic factors were analyzed retrospectively in 103 patients with brain metastases from lung carcinoma to identify patients who would benefit from more intensive treatment strategies.
Materials and methods: Between October 1991 and December 1994, 103 patients with brain metastasis from lung cancer were irradiated with palliative intent. Palliation was defined as 50% or more regression of neurological signs and symptoms 2 weeks after the completion of cranial radiotherapy. Local (related to the lung tumor) symptom status at the time of brain metastasis, the presence of metastases other than brain, multiplicity of brain metastases on CT scan and time of occurrence of brain metastasis were the factors which were evaluated with multivariate analysis.
Results: Palliation was accomplished in 85% of cases. Palliation duration ranged from 0.5 to 54 months (median 3 months). The overall median survival was 5 months. Only one patient is under follow-up without any symptoms related to the brain metastasis. According to the multivariate analysis survival was significantly decreased in the presence of symptoms related to the primary tumor (
P=0.001).
Conclusion: The presence of symptoms related to the primary tumor at the time of brain metastasis is one of the factors that can be used to distinguish patients with a favorable outcome. In patients with favorable prognostic factors and thus longer survival probability, the role of boost dose after whole brain radiotherapy or surgical resection in suitable cases needs to be investigated.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>9488125</pmid><doi>10.1016/S0167-8140(97)00124-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-8140 |
| ispartof | Radiotherapy and oncology, 1998, Vol.46 (1), p.33-38 |
| issn | 0167-8140 1879-0887 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79707029 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - radiotherapy Adenocarcinoma - secondary Adult Aged Aged, 80 and over Brain metastases Brain Neoplasms - mortality Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Small Cell - mortality Carcinoma, Small Cell - radiotherapy Carcinoma, Small Cell - secondary Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - secondary Female Follow-Up Studies Humans Lung cancer Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Multivariate Analysis Palliative Care Prognosis Prognostic factors Radiotherapy, Adjuvant Retrospective Studies Survival Rate Tomography, X-Ray Computed |
| title | Prognostic factors in lung cancer with brain metastasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A16%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20in%20lung%20cancer%20with%20brain%20metastasis&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=%C5%9Een,%20Mehmet&rft.date=1998&rft.volume=46&rft.issue=1&rft.spage=33&rft.epage=38&rft.pages=33-38&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/S0167-8140(97)00124-2&rft_dat=%3Cproquest_cross%3E79707029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79707029&rft_id=info:pmid/9488125&rft_els_id=S0167814097001242&rfr_iscdi=true |